Adult diagnoses (age 15 through 124)

Adult diagnoses (age 15 through 124). — See additional coding rules

T43.616D Underdosing of caffeine, subsequent encounter
T43.616S Underdosing of caffeine, sequela
T43.625A Adverse effect of amphetamines, initial encounter
T43.625D Adverse effect of amphetamines, subsequent encounter
T43.625S Adverse effect of amphetamines, sequela
T43.626A Underdosing of amphetamines, initial encounter
T43.626D Underdosing of amphetamines, subsequent encounter
T43.626S Underdosing of amphetamines, sequela
T43.635A Adverse effect of methylphenidate, initial encounter
T43.635D Adverse effect of methylphenidate, subsequent encounter
T43.635S Adverse effect of methylphenidate, sequela
T43.636A Underdosing of methylphenidate, initial encounter
T43.636D Underdosing of methylphenidate, subsequent encounter
T43.636S Underdosing of methylphenidate, sequela
T43.695A Adverse effect of other psychostimulants, initial encounter
T43.695D Adverse effect of other psychostimulants, subsequent encounter
T43.695S Adverse effect of other psychostimulants, sequela
T43.696A Underdosing of other psychostimulants, initial encounter
T43.696D Underdosing of other psychostimulants, subsequent encounter
T43.696S Underdosing of other psychostimulants, sequela
T43.8X5A Adverse effect of other psychotropic drugs, initial encounter
T43.8X5D Adverse effect of other psychotropic drugs, subsequent encounter
T43.8X5S Adverse effect of other psychotropic drugs, sequela
T43.8X6A Underdosing of other psychotropic drugs, initial encounter
T43.8X6D Underdosing of other psychotropic drugs, subsequent encounter
T43.8X6S Underdosing of other psychotropic drugs, sequela
T43.95XA Adverse effect of unspecified psychotropic drug, initial encounter
T43.95XD Adverse effect of unspecified psychotropic drug, subsequent encounter
T43.95XS Adverse effect of unspecified psychotropic drug, sequela
T43.96XA Underdosing of unspecified psychotropic drug, initial encounter
T43.96XD Underdosing of unspecified psychotropic drug, subsequent encounter
T43.96XS Underdosing of unspecified psychotropic drug, sequela
T44.0X5A Adverse effect of anticholinesterase agents, initial encounter
T44.0X5D Adverse effect of anticholinesterase agents, subsequent encounter
T44.0X5S Adverse effect of anticholinesterase agents, sequela
T44.0X6A Underdosing of anticholinesterase agents, initial encounter
T44.0X6D Underdosing of anticholinesterase agents, subsequent encounter
T44.0X6S Underdosing of anticholinesterase agents, sequela
T44.1X5A Adverse effect of other parasympathomimetics [cholinergics], initial encounter
T44.1X5D Adverse effect of other parasympathomimetics [cholinergics], subsequent encounter
T44.1X5S Adverse effect of other parasympathomimetics [cholinergics], sequela
T44.1X6A Underdosing of other parasympathomimetics [cholinergics], initial encounter
T44.1X6D Underdosing of other parasympathomimetics [cholinergics], subsequent encounter
T44.1X6S Underdosing of other parasympathomimetics [cholinergics], sequela
T44.2X5A Adverse effect of ganglionic blocking drugs, initial encounter
T44.2X5D Adverse effect of ganglionic blocking drugs, subsequent encounter
T44.2X5S Adverse effect of ganglionic blocking drugs, sequela
T44.2X6A Underdosing of ganglionic blocking drugs, initial encounter
T44.2X6D Underdosing of ganglionic blocking drugs, subsequent encounter
T44.2X6S Underdosing of ganglionic blocking drugs, sequela
T44.3X5A Adverse effect of other parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics, initial encounter
T44.3X5D Adverse effect of other parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics, subsequent encounter
T44.3X5S Adverse effect of other parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics, sequela
T44.3X6A Underdosing of other parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics, initial encounter
T44.3X6D Underdosing of other parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics, subsequent encounter
T44.3X6S Underdosing of other parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics, sequela
T44.4X5A Adverse effect of predominantly alpha-adrenoreceptor agonists, initial encounter
T44.4X5D Adverse effect of predominantly alpha-adrenoreceptor agonists, subsequent encounter
T44.4X5S Adverse effect of predominantly alpha-adrenoreceptor agonists, sequela
T44.4X6A Underdosing of predominantly alpha-adrenoreceptor agonists, initial encounter
T44.4X6D Underdosing of predominantly alpha-adrenoreceptor agonists, subsequent encounter
T44.4X6S Underdosing of predominantly alpha-adrenoreceptor agonists, sequela
T44.5X5A Adverse effect of predominantly beta-adrenoreceptor agonists, initial encounter
T44.5X5D Adverse effect of predominantly beta-adrenoreceptor agonists, subsequent encounter
T44.5X5S Adverse effect of predominantly beta-adrenoreceptor agonists, sequela
T44.5X6A Underdosing of predominantly beta-adrenoreceptor agonists, initial encounter
T44.5X6D Underdosing of predominantly beta-adrenoreceptor agonists, subsequent encounter
T44.5X6S Underdosing of predominantly beta-adrenoreceptor agonists, sequela
T44.6X5A Adverse effect of alpha-adrenoreceptor antagonists, initial encounter
T44.6X5D Adverse effect of alpha-adrenoreceptor antagonists, subsequent encounter
T44.6X5S Adverse effect of alpha-adrenoreceptor antagonists, sequela
T44.6X6A Underdosing of alpha-adrenoreceptor antagonists, initial encounter
T44.6X6D Underdosing of alpha-adrenoreceptor antagonists, subsequent encounter
T44.6X6S Underdosing of alpha-adrenoreceptor antagonists, sequela
T44.7X5A Adverse effect of beta-adrenoreceptor antagonists, initial encounter
T44.7X5D Adverse effect of beta-adrenoreceptor antagonists, subsequent encounter
T44.7X5S Adverse effect of beta-adrenoreceptor antagonists, sequela
T44.7X6A Underdosing of beta-adrenoreceptor antagonists, initial encounter
T44.7X6D Underdosing of beta-adrenoreceptor antagonists, subsequent encounter
T44.7X6S Underdosing of beta-adrenoreceptor antagonists, sequela
T44.8X5A Adverse effect of centrally-acting and adrenergic-neuron-blocking agents, initial encounter
T44.8X5D Adverse effect of centrally-acting and adrenergic-neuron-blocking agents, subsequent encounter
T44.8X5S Adverse effect of centrally-acting and adrenergic-neuron-blocking agents, sequela
T44.8X6A Underdosing of centrally-acting and adrenergic-neuron-blocking agents, initial encounter
T44.8X6D Underdosing of centrally-acting and adrenergic-neuron-blocking agents, subsequent encounter
T44.8X6S Underdosing of centrally-acting and adrenergic-neuron-blocking agents, sequela
T44.905A Adverse effect of unspecified drugs primarily affecting the autonomic nervous system, initial encounter
T44.905D Adverse effect of unspecified drugs primarily affecting the autonomic nervous system, subsequent encounter
T44.905S Adverse effect of unspecified drugs primarily affecting the autonomic nervous system, sequela
T44.906A Underdosing of unspecified drugs primarily affecting the autonomic nervous system, initial encounter
T44.906D Underdosing of unspecified drugs primarily affecting the autonomic nervous system, subsequent encounter
T44.906S Underdosing of unspecified drugs primarily affecting the autonomic nervous system, sequela
T44.995A Adverse effect of other drug primarily affecting the autonomic nervous system, initial encounter
T44.995D Adverse effect of other drug primarily affecting the autonomic nervous system, subsequent encounter
T44.995S Adverse effect of other drug primarily affecting the autonomic nervous system, sequela
T44.996A Underdosing of other drug primarily affecting the autonomic nervous system, initial encounter
T44.996D Underdosing of other drug primarily affecting the autonomic nervous system, subsequent encounter
T44.996S Underdosing of other drug primarily affecting the autonomic nervous system, sequela
T45.0X5A Adverse effect of antiallergic and antiemetic drugs, initial encounter
T45.0X5D Adverse effect of antiallergic and antiemetic drugs, subsequent encounter